44P Evaluation of immune response in young patients with sarcoma treated by dendritic cell-based immunotherapy

ConclusionCirculating cell-based immune markers revealed dose-dependent changes in subtle T-cell subsets during the course of DC treatment. Personalized anti-cancer DC-based ITx stimulates a pre-existing immune response against self-tumor antigens.Clinical trial identificationEudraCT: 2014-003388-39.Legal entity responsible for the studyCzech Ministry of Health.FundingCzech Ministry of Health (Projects LO1413, LM2015090, academic clinical trial).DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research